Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using EGFR-targeting Agent

Review the clinical trials studying egfr-targeting agent on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 182

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 453 locations
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 422 locations
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Status: Active
Location: 557 locations
Testing Osimertinib as a Treatment for Lung Cancers with an EGFR Exon 20 Change
Status: Active
Location: 246 locations
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Status: Active
Location: 254 locations
Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Status: Active
Location: 206 locations
Testing the use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Status: Active
Location: 174 locations
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Status: Active
Location: 157 locations
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer after Previous Treatment
Status: Active
Location: 153 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 55 locations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 43 locations
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Status: Active
Location: 35 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 34 locations
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Status: Active
Location: 31 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 22 locations
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 18 locations
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers with Changes in the HER2 Gene
Status: Active
Location: 18 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 17 locations
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Status: Active
Location: 18 locations
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Status: Active
Location: 16 locations
Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers
Status: Active
Location: 16 locations
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Status: Active
Location: 16 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Status: Active
Location: 16 locations